Pfizer is navigating a transitional phase aiming for growth by 2029, maintaining its dividend payout to support financial stability despite patent losses and reduced COVID revenues. The company’s dividend payout ratio aligns with management’s long-term goal, reflecting a cautious but steady approach. The article also explores tax-free high-yield municipal bond ETFs, noting their federal tax advantages but potential state tax and alternative minimum tax implications. Additionally, mortgage REITs like AGNC and NLY are viewed skeptically, while stocks like Gladstone Land and the Virtus InfraCap Preferred Stock ETF are added to a watchlist for their unique income strategies and yields.
Innovent Biologics has entered a $10.5 billion partnership with Pfizer to co-develop and co-commercialize a portfolio of 12 early-stage cancer medicines, focusing on antibody-drug conjugates. Innovent will share costs and profits with Pfizer in the U...
Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop 12 early-stage cancer medicines, including antibody-drug conjugates and multi-specific antibodies. Innovent will lead initial developmen...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
